New Multi-Center Accelerate Pheno® Study: Significant Improvements in Multiple Outcomes for Gram-Positive Bloodstream Infections
May 22, 2021
A new, multicenter study published today in the Journal of Antimicrobial Chemotherapy shows that use of the Accelerate Pheno system for identification and antimicrobial susceptibility testing of Gram-positive bloodstream infections supports improvements in multiple important clinical outcomes, including:
- Reduction in time to optimal therapy (TTOT) of 15.9 hours
- Reduction in time to first antibiotic modification and time to first Gram-positive antibiotic modification
- Shorter duration of unnecessary MRSA coverage by 28.7 hours
- A trend toward decreased acute kidney injury from 24% to 13%
“This is the first study exclusively focused on use of the Accelerate Pheno system for testing Gram-positive bloodstream infections, and we were pleased to find the benefits in this patient population were consistent with those found in other studies,” said Shawn MacVane, PharmD, the study’s lead author.
The study’s sites included the University of Arkansas for Medical Sciences and the University of Iowa, members of the Improving Outcomes and Antibiotic Stewardship (IOAS) study group, which also includes Cedars-Sinai Medical Center, Allegheny General Hospital, and MD Anderson Cancer Center.
The full publication is available for open access at https://doi.org/10.1093/jac/dkab165.
- New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021
Jun 30, 2021
- Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections
Jun 08, 2021